Investigating new treatment targets for T-cell leukemia
ETS1-dependent combinatorial control of oncogenic transcription in Notch-activated T-ALL
This study is looking at how specific proteins in the body can help us find safer ways to treat T-cell acute lymphoblastic leukemia (T-ALL) without hurting the intestines, using mouse models to test these new treatment ideas.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11075236 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain transcription factors interact with the Notch signaling pathway in T-cell acute lymphoblastic leukemia (T-ALL). By identifying these transcription factors, the study aims to find safer therapeutic targets that can inhibit T-ALL without causing harmful side effects, particularly to the intestines. The approach involves using mouse models to test the effects of targeting these factors, which could lead to more effective treatments for patients with T-ALL. The research builds on previous findings that highlight the role of ETS1 as a key player in this process.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with T-cell acute lymphoblastic leukemia, both children and adults.
Not a fit: Patients with other types of leukemia or those who do not have T-cell acute lymphoblastic leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients with T-cell leukemia.
How similar studies have performed: Other research has shown promise in targeting transcription factors in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Chiang, Mark Y — University of Michigan at Ann Arbor
- Study coordinator: Chiang, Mark Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.